-
Featured
Advanced Technology Improves Cervical Spine Surgery Outcomes
Surgeons in Massachusetts General Hospital's Neurosurgical Spine Service use a multidisciplinary approach to treat cervical spine deformities with complex surgeries using innovative technology including artificial intelligence.
-
Featured
Finding New Approaches to Treat Desmoid Tumor Patients
Surgery for desmoid tumors is only about 50% effective. Multidisciplinary care may be more effective for helping patients find relief.
Learn About the Bone Cancer (Osteosarcoma) Treatment Program
Orthopaedic Oncology contributors
-
Erik T. Newman, MD
Orthopaedic Oncology Surgeon, Department of Orthopaedics, Massachusetts General Hospital, Instructor in Orthopaedic Surgery, Harvard Medical School
Recent Article
Local Treatment of Extremity Desmoid Tumors Does Not Improve Survival, Function -
John H. Shin, MD
Director, Spinal Deformity and Spine Oncology (Mass General Cancer Center), Spinal Reconstruction Surgery
Recent Article
Advanced Technology Improves Cervical Spine Surgery Outcomes
-
Joseph H. Schwab, MD
Chief, Orthopaedic Spine Surgery, Director, Spine Oncology & Co-Director, Stephen L. Harris Chordoma Center, Associate Professor of Orthopedic Surgery, Harvard Medical School
Recent Article
Minor Complications Associated with Increased Mortality Risk After Surgery for Metastases in Long Bones
-
Kevin Andrew Raskin, MD
Acting Chief, Orthopaedic Oncology Service, Program Director, Musculoskeletal Oncology Fellowship Program, Assistant Professor of Orthopaedic Surgery, Harvard Medical School
Recent Article
Finding New Approaches to Treat Desmoid Tumor Patients
-
Santiago A. Lozano Calderon, MD, PhD
Orthopaedic Oncology Surgeon, Instructor in Orthopaedic Surgery, Harvard Medical School
Recent Article
Local Treatment of Extremity Desmoid Tumors Does Not Improve Survival, Function
Orthopaedic Oncology Service at Mass General
As members of the Cancer Center at Massachusetts General Hospital, the Orthopaedic Oncology team provides compassionate care to children, adolescents and adults with primary bone and soft tissue tumors (benign and malignant) and metastatic.
